research use only

Idebenone ROS chemical

Name: Idebenone
Brand: Selleck Chemicals
SKU: S2605
Availability: InStock
Rating: 5 (4 reviews)

Cat.No.S2605

Idebenone (CV-2619) is a synthetic analog of coenzyme Q10 (CoQ10) and a brain stimulant. This compound is known for its neuroprotective properties and is often used in research related to mitochondrial diseases. It has also been studied for its potential benefits in treating cognitive decline.

Chemical Structure

Molecular Weight: 338.44

Jump to Mechanism of Action Solubility Chemical Information, Storage & Stability Specificity

Quality Control

Batch: Purity: 99.97%

99.97

Related Targets	Immunology & Inflammation related CD markers Interleukins Anti-infection Antioxidant COX Histamine Receptor TNF-alpha Parasite PD-1/PD-L1 TLR Prostaglandin Receptor IFN CXCR Nrf2 NOS CCR NLRP3 eIF STING AhR IL Receptor Complement System IRAK β-lactamase IDO/TDO PGES FKBP NADPH-oxidase LTR
Related Products	Piperlongumine MitoQ (Mitoquinone) Mesylate H2DCFDA (DCFH-DA) Neohesperidin Carnosic acid Gallic acid (20R)Ginsenoside Rg3 Pyrogallol Asiaticoside Sarsasapogenin Troxerutin Raspberry ketone glucoside Chicoric acid Sanguinarine citrate MCB-613 Ecabet sodium Dehydroevodiamine Nerol Baohuoside I L-SelenoMethionine Isochlorogenic acid C Efaproxiral Sodium Kelp Extract Glycitein Ensulizole Oyster Peptide Pyrroloquinoline quinone

Chemical Information, Storage & Stability

Molecular Weight	338.44	Formula	C₁₉H₃₀O₅	Storage (From the date of receipt)	3 years-20°Cpowder
CAS No.	58186-27-9	Download SDF		Storage of Stock Solutions	1 year-80°Cin solvent 1 month-20°Cin solvent
Synonyms	CV-2619			Smiles	CC1=C(C(=O)C(=C(C1=O)OC)OC)CCCCCCCCCCO

Solubility

In vitro
Batch:

DMSO : 68 mg/mL (200.92 mM)
(Moisture-contaminated DMSO may reduce solubility. Use fresh, anhydrous DMSO.)

Ethanol : 68 mg/mL

Water : Insoluble

Molarity Calculator

Mass	Concentration	Volume	Molecular Weight
=	×	×

Dilution Calculator Molecular Weight Calculator

In vivo Batch:
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Clear solution	5%DMSO 1 40%PEG300 2 5%Tween80 3 50%ddH2O Validated by Selleck labs. Should you need adjustments to this formulation, contact our sales team for custom testing.	3.4mg/ml (10.05mM)	Taking the 1 mL working solution as an example, add 50 μL of 68 mg/ml clarified DMSO stock solution to 400 μL of PEG300, mix evenly to clarify it; add 50 μL of Tween80 to the above system, mix evenly to clarify; then continue to add 500 μL of ddH2O to adjust the volume to 1 mL. The mixed solution should be used immediately for optimal results.
Clear solution	5% DMSO 1 95% Corn oil Validated by Selleck labs. Should you need adjustments to this formulation, contact our sales team for custom testing.	3.4mg/ml (10.05mM)	Taking the 1 mL working solution as an example, add 50 μL of 68 mg/ml clear DMSO stock solution to 950 μL of corn oil and mix evenly. The mixed solution should be used immediately for optimal results.

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage: mg/kg Average weight of animals: g Dosing volume per animal:μL Number of animals:

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO + % + % Tween 80 + % ddH₂O

%DMSO+ %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH₂O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Mechanism of Action

In vitro	Idebenone effectively protects from retinal cell injury after oxidative stress or hypoglycemia, whereas the protection afforded after postincubation of both antioxidants is decreased. This compound attenuates delayed retinal cell damage, mediated by chemical ischemia. ^[1] This chemical, a centrally active antioxidant used to treat multiinfarct dementia, protects cells from this form of glutamate-induced cytotoxicity in vitro. It provides significant protection against the neuronal degeneration induced by intrastriatal injection of kainic acid and quisqualic acid, but not the NMDA receptor agonist, quinolinic acid. ^[2]
In vivo	Idebenone prevents the behavioural deficits in Y-maze and water maze, but not passive avoidance, tasks in A beta-(1-42)-infused rats when they are repeatedly administered by mouth once a day from 3 days before the start of A beta infusion to the end of behavioural experiments. ^[3] This compound (100 and 300 mg/kg) is orally administered to rats for 3 days, it increases the state 3 respiration stimulated by ADP, slightly decreasez the state 4 respiration after the consumption of ADP and resultz in a significant increase of the respiratory control index (RCI) by 14-19% for glutamate oxidation and 10-17% for succinate oxidation, respectively. It significantly suppresses by about 10% the non-respiratory oxygen consumption, which closely associated with non-enzymatic reactions such as lipid peroxidation, membrane lysis and swelling of mitochondria. ^[4]
References	[1] https://pubmed.ncbi.nlm.nih.gov/10401604/ [2] https://pubmed.ncbi.nlm.nih.gov/9987013/ [3] https://pubmed.ncbi.nlm.nih.gov/2138566/ [4] https://pubmed.ncbi.nlm.nih.gov/3987906/

Clinical Trial Information

(data from https://clinicaltrials.gov, updated on 2024-05-22)

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT01303406	Completed	Friedreich''s Ataxia	Santhera Pharmaceuticals	April 2011	Phase 3
NCT00758225	Completed	Duchenne Muscular Dystrophy	Santhera Pharmaceuticals	September 2008	Phase 2
NCT00747487	Completed	Leber''s Hereditary Optic Neuropathy	Santhera Pharmaceuticals	November 2007	Phase 2
NCT00229632	Completed	Friedreich Ataxia	National Institute of Neurological Disorders and Stroke (NINDS)\|National Institutes of Health Clinical Center (CC)	September 27 2005	Phase 2

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):